JP2002513392A5 - - Google Patents

Download PDF

Info

Publication number
JP2002513392A5
JP2002513392A5 JP1998524895A JP52489598A JP2002513392A5 JP 2002513392 A5 JP2002513392 A5 JP 2002513392A5 JP 1998524895 A JP1998524895 A JP 1998524895A JP 52489598 A JP52489598 A JP 52489598A JP 2002513392 A5 JP2002513392 A5 JP 2002513392A5
Authority
JP
Japan
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP1998524895A
Other languages
English (en)
Japanese (ja)
Other versions
JP2002513392A (ja
JP5173089B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US1997/022016 external-priority patent/WO1998023263A1/en
Publication of JP2002513392A publication Critical patent/JP2002513392A/ja
Publication of JP2002513392A5 publication Critical patent/JP2002513392A5/ja
Application granted granted Critical
Publication of JP5173089B2 publication Critical patent/JP5173089B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

JP52489598A 1996-11-25 1997-11-12 上昇する投与量の薬剤投与型 Expired - Lifetime JP5173089B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US3174196P 1996-11-25 1996-11-25
US60/031,741 1996-11-25
US96760697A 1997-11-10 1997-11-10
US08/967,606 1997-11-10
PCT/US1997/022016 WO1998023263A1 (en) 1996-11-25 1997-11-12 Ascending-dose dosage form

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2010099006A Division JP5215347B2 (ja) 1996-11-25 2010-04-22 上昇する投与量の薬剤投与型

Publications (3)

Publication Number Publication Date
JP2002513392A JP2002513392A (ja) 2002-05-08
JP2002513392A5 true JP2002513392A5 (cg-RX-API-DMAC10.html) 2005-08-11
JP5173089B2 JP5173089B2 (ja) 2013-03-27

Family

ID=26707551

Family Applications (2)

Application Number Title Priority Date Filing Date
JP52489598A Expired - Lifetime JP5173089B2 (ja) 1996-11-25 1997-11-12 上昇する投与量の薬剤投与型
JP2010099006A Expired - Lifetime JP5215347B2 (ja) 1996-11-25 2010-04-22 上昇する投与量の薬剤投与型

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2010099006A Expired - Lifetime JP5215347B2 (ja) 1996-11-25 2010-04-22 上昇する投与量の薬剤投与型

Country Status (11)

Country Link
EP (1) EP0946151B1 (cg-RX-API-DMAC10.html)
JP (2) JP5173089B2 (cg-RX-API-DMAC10.html)
CN (2) CN1182839C (cg-RX-API-DMAC10.html)
AT (1) ATE325606T1 (cg-RX-API-DMAC10.html)
AU (1) AU5267698A (cg-RX-API-DMAC10.html)
CA (1) CA2265668C (cg-RX-API-DMAC10.html)
DE (1) DE69735848T2 (cg-RX-API-DMAC10.html)
DK (1) DK0946151T3 (cg-RX-API-DMAC10.html)
ES (1) ES2264173T3 (cg-RX-API-DMAC10.html)
PT (1) PT946151E (cg-RX-API-DMAC10.html)
WO (1) WO1998023263A1 (cg-RX-API-DMAC10.html)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6440457B1 (en) 1993-05-27 2002-08-27 Alza Corporation Method of administering antidepressant dosage form
US5922736A (en) 1995-12-04 1999-07-13 Celegene Corporation Chronic, bolus administration of D-threo methylphenidate
US6486177B2 (en) 1995-12-04 2002-11-26 Celgene Corporation Methods for treatment of cognitive and menopausal disorders with D-threo methylphenidate
US5837284A (en) * 1995-12-04 1998-11-17 Mehta; Atul M. Delivery of multiple doses of medications
US6919373B1 (en) 1996-11-12 2005-07-19 Alza Corporation Methods and devices for providing prolonged drug therapy
US6962997B1 (en) 1997-05-22 2005-11-08 Celgene Corporation Process and intermediates for resolving piperidyl acetamide steroisomers
KR100827254B1 (ko) 1998-06-03 2008-05-07 알자 코포레이션 연장된 약물 치료를 제공하기 위한 방법 및 장치
US7083808B2 (en) 1998-12-17 2006-08-01 Euro-Celtique S.A. Controlled/modified release oral methylphenidate formulations
US6419960B1 (en) 1998-12-17 2002-07-16 Euro-Celtique S.A. Controlled release formulations having rapid onset and rapid decline of effective plasma drug concentrations
US6673367B1 (en) * 1998-12-17 2004-01-06 Euro-Celtique, S.A. Controlled/modified release oral methylphenidate formulations
US6395752B1 (en) * 1999-03-04 2002-05-28 Pharmaquest Limited Method of treating depression using 1-threo-methylphenidate
US6127385A (en) * 1999-03-04 2000-10-03 Pharmaquest Limited Method of treating depression using l-threo-methylphenidate
WO2003005951A2 (en) 2001-07-10 2003-01-23 Teva Pharmaceutical Industries Ltd. Drug delivery system for zero order, zero order-biphasic, ascending or descending drug delivery
WO2003057136A2 (en) 2001-12-24 2003-07-17 Teva Pharmaceutical Industries Ltd. Dosage form with a core tablet of active ingredient sheathed in a compressed annular body of powder or granular material, and process and tooling for producing it
US20050232995A1 (en) 2002-07-29 2005-10-20 Yam Nyomi V Methods and dosage forms for controlled delivery of paliperidone and risperidone
US7988993B2 (en) 2002-12-09 2011-08-02 Andrx Pharmaceuticals, Inc. Oral controlled release dosage form
MXPA06003452A (es) * 2003-09-26 2006-08-31 Johnson & Johnson Formulaciones de liberacion controlada que exhiben una velocidad de liberacion ascendente.
US8541026B2 (en) 2004-09-24 2013-09-24 Abbvie Inc. Sustained release formulations of opioid and nonopioid analgesics
PL116330U1 (en) 2005-10-31 2007-04-02 Alza Corp Method for the reduction of alcohol provoked rapid increase in the released dose of the orally administered opioide with prolonged liberation
US20100151020A1 (en) 2008-12-16 2010-06-17 Vered Rosenberger Drug delivery system for zero order, zero order biphasic, ascending or descending drug delivery of methylphenidate
US11241391B2 (en) 2011-03-23 2022-02-08 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US10292937B2 (en) 2011-03-23 2019-05-21 Ironshore Pharmaceuticals & Development, Inc. Methods of treatment of attention deficit hyperactivity disorder
US8927010B2 (en) 2011-03-23 2015-01-06 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US9603809B2 (en) 2011-03-23 2017-03-28 Ironshore Pharmaceuticals & Development, Inc. Methods of treatment of attention deficit hyperactivity disorder
DK3272342T3 (da) 2011-03-23 2021-06-07 Ironshore Pharmaceuticals & Dev Inc Fremgangsmåder og sammensætninger til behandling af opmærksomhedsforstyrrelse
US10905652B2 (en) 2011-03-23 2021-02-02 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US9283214B2 (en) 2011-03-23 2016-03-15 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US9498447B2 (en) 2011-03-23 2016-11-22 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US8916588B2 (en) 2011-03-23 2014-12-23 Ironshore Pharmaceuticals & Development, Inc. Methods for treatment of attention deficit hyperactivity disorder
US9119809B2 (en) 2011-03-23 2015-09-01 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
CA2936746C (en) 2014-10-31 2017-06-27 Purdue Pharma Methods and compositions particularly for treatment of attention deficit disorder
US10722473B2 (en) 2018-11-19 2020-07-28 Purdue Pharma L.P. Methods and compositions particularly for treatment of attention deficit disorder

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4327725A (en) * 1980-11-25 1982-05-04 Alza Corporation Osmotic device with hydrogel driving member
US5082668A (en) * 1983-05-11 1992-01-21 Alza Corporation Controlled-release system with constant pushing source
CA2007181C (en) * 1989-01-06 1998-11-24 Angelo Mario Morella Sustained release pharmaceutical composition
US5024843A (en) * 1989-09-05 1991-06-18 Alza Corporation Oral hypoglycemic glipizide granulation
WO1992001445A1 (en) * 1990-07-23 1992-02-06 Alza Corporation Oral osmotic device for delivering nicotine
US5156850A (en) * 1990-08-31 1992-10-20 Alza Corporation Dosage form for time-varying patterns of drug delivery
US5166145A (en) * 1990-09-10 1992-11-24 Alza Corporation Antiemetic therapy
US5208037A (en) * 1991-04-22 1993-05-04 Alza Corporation Dosage forms comprising polymers comprising different molecular weights
EP0664118B1 (en) * 1991-10-04 1999-08-25 Yoshitomi Pharmaceutical Industries, Ltd. Sustained-release tablet
US5532003A (en) * 1994-01-18 1996-07-02 Alza Corporation Pentoxifylline therapy
ZA953078B (en) * 1994-04-28 1996-01-05 Alza Corp Effective therapy for epilepsies
US5698224A (en) * 1994-06-27 1997-12-16 Alza Corporation Tacrine therapy
US5614578A (en) * 1994-10-28 1997-03-25 Alza Corporation Injection-molded dosage form
ES2194210T3 (es) * 1996-08-16 2003-11-16 Alza Corp Forma de dosificacion para suministrar una dosis ascendente de farmaco.

Similar Documents

Publication Publication Date Title
JP2000502280A5 (cg-RX-API-DMAC10.html)
JP2000501771A5 (cg-RX-API-DMAC10.html)
JP2000501599A5 (cg-RX-API-DMAC10.html)
JP2001507641A5 (cg-RX-API-DMAC10.html)
JP2000507746A5 (cg-RX-API-DMAC10.html)
JP2000502472A5 (cg-RX-API-DMAC10.html)
JP2000501825A5 (cg-RX-API-DMAC10.html)
JP2000515385A5 (cg-RX-API-DMAC10.html)
JP2000516201A5 (cg-RX-API-DMAC10.html)
JP2002507130A5 (cg-RX-API-DMAC10.html)
JP2000513889A5 (cg-RX-API-DMAC10.html)
JP2000502425A5 (cg-RX-API-DMAC10.html)
JP2000502485A5 (cg-RX-API-DMAC10.html)
JP2000502568A5 (cg-RX-API-DMAC10.html)
JP2000501774A5 (cg-RX-API-DMAC10.html)
JP2000502570A5 (cg-RX-API-DMAC10.html)
JP2000501876A5 (cg-RX-API-DMAC10.html)
JP2002504242A5 (cg-RX-API-DMAC10.html)
JP2000501744A5 (cg-RX-API-DMAC10.html)
JP2002513392A5 (cg-RX-API-DMAC10.html)
JP2000502316A5 (cg-RX-API-DMAC10.html)
JP2000502714A5 (cg-RX-API-DMAC10.html)
JP2000515924A5 (cg-RX-API-DMAC10.html)
JP2000501569A5 (cg-RX-API-DMAC10.html)
JP2001503316A5 (cg-RX-API-DMAC10.html)